OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
With vaccine development prioritized during the COVID-19 pandemic, innovations have to accelerated development processes.
The inhaled route of administration for biologics is experiencing renewed interest.
June 02, 2021
GoSilico’s software for digital twins of downstream biopharmaceutical processes will be integrated into Cytiva.
Currently, PNI offers a Genetic Medicine Toolkit, including its GenVoy LNP delivery platform and NanoAssemblr microfluidic-based nanoparticle manufacturing platform, for the development of genetic medicines.
The emergence of new biotherapeutics is both the driver and result of innovative drug development technologies.
Controlling certain atmospheric conditions in a closed NGI processing chamber can reduce bioburden without disinfectants.
Contract manufacturers play a key role in the production of lipid nanoparticles for RNA vaccines.
June 01, 2021
Outsourcing method development offers multiple benefits to companies, including access to experience and expertise, streamlined costs, and development time efficiencies.
May 21, 2021
Developing and manufacturing a therapy in a regulated environment demands careful adherence to quality practices.
May 20, 2021
Under the terms of the agreement, Thermo Fisher will construct and operate a 44,000-ft2 cell therapy development, manufacturing, and collaboration center on UCSF's Mission Bay campus.
May 19, 2021
Bristol Myers Squibb has entered into a definitive agreement with Agenus for a global exclusive license to Agenus’ proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target.
May 17, 2021
Charles River plans to enhance its gene therapy capabilities through the acquisition of Vigene Biosciences.